NCT03063489View on ClinicalTrials.gov

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

July 31, 2015

Conditions
Eye Pain
Interventions
DRUG

Loteprednol Etabonate Ophthalmic Gel

Formulated LE into a gel (loteprednol etabonate ophthalmic gel, \[Lotemax® gel\])

Trial Locations (6)

33143

Valeant Site 05, Miami

63131

Valeant Site 02, St Louis

64111

Valeant Site 06, Kansas City

85032

Valeant Site 01, Phoenix

92056

Valeant Site 03, Oceanside

01269

Valeant Site 04, Quincy

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03063489 - Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability | Biotech Hunter | Biotech Hunter